April 6, 2010
Menlo Park, CA
March has brought significant changes in biotech-related law. The Federal Circuit’s decision in Ariad confirmed that section 112 of the Patent Act contains a written description requirement separate and apart from the enablement requirement and articulated “a few broad principles” that the Court said “hold across all cases.” On the legislative front, the new healthcare legislation included the “Biologics Price Competition and Innovation Act of 2009,” which creates the legal and regulatory framework for the approval of follow-on biologics (“FOBs”).
What does all of this mean to patent practitioners in the biotech industry? Please join our panelists as they discuss:
– The impact of Ariad
– What to expect for biosimilars
Finnegan confirms that this activity has been certified for 1.5 hours of California MCLE.
Date:
Tuesday, April 6, 2010
Time:
7:45-8:15 a.m. - Registration and breakfast
8:15-10:15 a.m. - Program
Where:
Quadrus Conference Center
2400 Sand Hill Road
Menlo Park, CA 94025
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.